Benefits and Costs of Recombinant Human Erythropoietin for End-Stage Renal Failure: A Review: Benefits and Costs of Erythropoietin
1993 ◽
Vol 9
(4)
◽
pp. 490-504
◽
Keyword(s):
AbstractRecombinant human erythropoietin is an efficacious therapy in treatment of the anemia of end-stage renal failure. However, the scale of impact on quality of life and medical care resources remains uncertain. By reviewing the literature we evaluate cost-effectiveness of recombinant human erythropoietin and show how previous studies may have implicitly overestimated cost-effectiveness.
2001 ◽
Vol 6
(3)
◽
pp. 658-670
◽
1988 ◽
Vol 319
(20)
◽
pp. 1353-1354
◽
2004 ◽
Vol 20
(3)
◽
pp. 258-268
◽
Keyword(s):
Keyword(s):
2000 ◽
Vol 15
(9)
◽
pp. 1425-1430
◽
Keyword(s):